Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178533 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL21286088 | 1.00 | TAAR1 (0.63) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL23524375 | 0.98 | TAAR1 (0.61) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL13996924 | 0.81 | CYP1A2 (0.66) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL11162290 | 0.81 | SLC6A2 (0.55) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL178625 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL6077438 | 0.80 | SLC6A2 (0.54) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL10076448 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL765297 | 0.80 | TAAR1 (0.65) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL7343144 | 0.79 | SLC6A2 (0.59) | TAAR1SLC18A2SIGMAR1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11761954-B2 | NBOMe test | UNIVERSITY OF TECHNOLOGY SYDNEY | 2023-09-19 | — | — | US | disclosed |
| WO-2019161162-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2000054773-A1 | DOPAMINE AGONISTS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4521421-A | USING 2-AMINO-OCTAHYDROPYRIMIDO(4,5-G)QUINOLINE COMPOUND | ELI LILLY AND COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| US-4314081-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4194009-A | ANTIDEPRESSANT | ELI LILLY AND COMPANY (US) | 1980-03-18 | — | — | US | disclosed |
| US-4018895-A | Aryloxyphenylpropylamines in treating depression | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |